The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette‐Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|5|753-763

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.5, 2015-11, pp. : 753-763

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer

By  

Current Urology, Vol. 6, Iss. 3, 2012-12 ,pp. : 160-164

Karger

Access to resources Recommend Favorite

Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy

By Nemeth Johannes  

Wiener klinische Wochenschrift, Vol. 120, Iss. 3-4, 2008-02 ,pp. : 121-123

Springer Publishing Company

Access to resources Recommend Favorite

Autoimmune Clinical Manifestations following Intravesical Bacillus Calmette-Guérin and Interferon alpha 2b Immunotherapy for Superficial Bladder Cancer

By  

Current Urology, Vol. 3, Iss. 1, 2009-05 ,pp. : 36-40

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review

By  

Urologia Internationalis, Vol. 99, Iss. 1, 2017-06 ,pp. : 1-5

Karger

Access to resources Recommend Favorite

Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 80, Iss. 1, 2008-01 ,pp. : 74-79

Karger

Access to resources Recommend Favorite